SHP.L - Shire plc

LSE - LSE Delayed Price. Currency in GBp
4,133.50
+30.50 (+0.74%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous Close4,103.00
Open4,130.00
Bid4,000.50 x 51000
Ask4,150.00 x 53800
Day's Range4,103.50 - 4,144.00
52 Week Range2,940.50 - 4,676.26
Volume1,386,373
Avg. Volume4,909,812
Market Cap37.741B
Beta1.32
PE Ratio (TTM)8.49
EPS (TTM)486.70
Earnings DateAug 2, 2018
Forward Dividend & Yield0.25 (0.60%)
Ex-Dividend Date2018-03-08
1y Target Est59.24
  • GlobeNewswire4 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire4 days ago

    Shire plc : Block listing Interim Review

    BLOCK LISTING SIX MONTHLY RETURN May 23, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) Name of applicant : Shire plc Name of scheme: Shire Sharesave Scheme Period of return: From: November 23, 2017 To:  May ...

  • GlobeNewswire5 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire5 days ago

    Shire plc : Director Declaration

    Director Declaration May 22, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Olivier Bohuon, Senior Independent Director of the Company, is to be appointed as a Non-Executive ...

  • Ahead of Shire buyout, Takeda sells joint venture and reportedly plans $20B bond deal
    American City Business Journals5 days ago

    Ahead of Shire buyout, Takeda sells joint venture and reportedly plans $20B bond deal

    The $62 billion Shire takeover, which Takeda expects to close in the first half of 2019, will create the the largest life sciences employer in Massachusetts.

  • GlobeNewswire6 days ago

    Shire announces new hypoparathyroidism data at the 2018 European Congress of Endocrinology

    May 22, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, presents new data on recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) in patients with chronic hypoparathyroidism at the 20th European Congress of Endocrinology (ECE 2018), from 19-22 May 2018, in Barcelona, Spain. The latest studies provide valuable insights into the burden of the disease and impact of treatment in patients with chronic hypoparathyroidism, a rare endocrine disease.

  • GlobeNewswire6 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • Roche Proves Again Why It Will Likely Rout Shire's Hemophilia Business
    Investor's Business Daily6 days ago

    Roche Proves Again Why It Will Likely Rout Shire's Hemophilia Business

    Roche jumped early Monday on unsurprisingly strong data for its hemophilia treatment, Hemlibra — prodding shares of Shire to slip.

  • GlobeNewswire7 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • Financial Times7 days ago

    [$$] Takeda says Shire deal will boost resilience against price pressures

    will strengthen the Japanese group’s focus on innovative medicines and make it more “resilient” to pricing pressures in the US, its chief executive has said. , Mr Weber said, had been designed “in a way” that meant the combined company “would be very resilient and prepared for an environment which will become tougher”. In 2017, the US accounted for 66 per cent of Shire’s $15bn sales.

  • Benzinga8 days ago

    Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

    The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...

  • GlobeNewswire10 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal
    Reuters10 days ago

    Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

    For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion (46 billion pound) deal last week to buy drugmaker Shire (SHP.L) at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor.

  • Biogen, Shire called out by FDA for ‘gaming’ generic access rule
    American City Business Journals10 days ago

    Biogen, Shire called out by FDA for ‘gaming’ generic access rule

    The FDA’s decision to publish a list of companies accused of blocking access to their product samples is part of a broader effort by the Trump administration to address high drug costs.

  • Reuters10 days ago

    FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal

    For Christophe Weber, the boss of Japan's Takeda Pharmaceutical, securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor. When you combine two pipelines you can be more stringent," he said in London, where he is meeting investors and analysts.

  • GlobeNewswire12 days ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • PR Newswire13 days ago

    Shire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing Diseases Awareness

    LEXINGTON, Mass., May 15, 2018 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces its third annual #FlyforMPS campaign to allow rare champions around the world to recognize and raise awareness for patients and caregivers affected by MPS (mucopolysaccharide) diseases. Shire's #FlyforMPS campaign was created in support of MPS Awareness Day, held annually on May 15th. The campaign was developed in collaboration with the National MPS Society and U.K. MPS Society.

  • GlobeNewswire13 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • Motley Fool13 days ago

    Takeda and Shire: A Pricey Marriage

    A deal gets done, but the costs are high.

  • Motley Fool13 days ago

    Will athenahealth Be the Next Big Healthcare Deal?

    Activist investors want to do a deal, but management might not be willing.

  • Is There An Opportunity With Shire plc’s (LON:SHP) 26% Undervaluation?
    Simply Wall St.13 days ago

    Is There An Opportunity With Shire plc’s (LON:SHP) 26% Undervaluation?

    I am going to run you through how I calculated the intrinsic value of Shire plc (LSE:SHP) using the discounted cash flow (DCF) method. If you want to learn moreRead More...

  • Value Stocks Investors Love
    Simply Wall St.15 days ago

    Value Stocks Investors Love

    Companies, such as Trading Emissions, trading at a market price below their true values are considered to be undervalued. There’s a few ways you can determine how much a companyRead More...

  • Iconic Genzyme building faces uncertain future after Shire-Takeda deal
    American City Business Journals17 days ago

    Iconic Genzyme building faces uncertain future after Shire-Takeda deal

    Shire had been planning to move into the building early next year. Takeda's $62 billion buyout this week could throw a wrench in the works.

  • GlobeNewswire17 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...